Login to Your Account



Lung liver the wall crashed through

Aria happy now? Madrigal proves Synta merger smart; swift phase II NASH results

By Randy Osborne
Staff Writer

Thursday, December 7, 2017

Madrigal Pharmaceuticals Inc. is waiting on further data to provide firm guidance about a potential phase III trial, but shares (NASDAQ:MDGL) meanwhile soared 88.3 percent, or $40.88, to close Wednesday at $87.18 on word of positive top-line findings from a phase II experiment in nonalcoholic steatohepatitis (NASH) with MGL-3196, a first-in-class, oral, once-daily, liver-directed, thyroid hormone receptor beta-selective agonist.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription